Inclisiran

Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) [1][2][3].

Product Specifications

CAS Number

[1639324-58-5]

Product Name Alternative

ALN-PCSsc

UNSPSC

12352208

Hazard Statement

H302, H315, H319, H335

Target

Caspase; Interleukin Related; NOD-like Receptor (NLR) ; PCSK9; PPAR; Pyroptosis; Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/inclisiran.html

Purity

99.71

Solubility

H2O : 5 mg/mL (ultrasonic)

Smiles

[Inclisiran]

Molecular Formula

C529H707F12N176O316P43S6

Molecular Weight

16339.00

Precautions

H302, H315, H319, H335

References & Citations

[1]Constantine E Kosmas, et al. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Ther Clin Risk Manag. 2020 Oct 28;16:1031-1037.|[2]Kong N, Xu Q, Cui W, Feng X, Gao H. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis. Ann Transl Med. 2022;10 (22) :1205.|[3]Wang Z, et al. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway. Autoimmunity. 2022 Jun;55 (4) :223-232.